Key Segmentation
By Vector Type
- Adenovirus
- Adeno-Associated Virus (AAV)
- Lentivirus
- Retrovirus
- Plasmids
- Others
By Workflow
- Upstream Manufacturing
- Downstream Purification
- Fill-Finish
- Quality Control & Testing
- Process Development
By Application
- Gene Therapy
- Cell Therapy
- Vaccines
- Oncology/Oncolytic Viruses
- Research Use
By Grade
- Research-Grade
- GMP-Grade (Clinical)
- GMP-Grade (Commercial)
By End User
- Biopharmaceutical & Biotechnology Companies
- CDMOs/CMOs
- Academic & Research Institutes
- Vaccine Manufacturers
- Government/Public Health Agencies
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g. Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market is expected to grow at a CAGR of 15.22% between 2026 and 2035.
The market was valued at USD 7.17 Billion in 2025.
Adeno-Associated Virus (AAV) held the largest share in 2025, at 29% of total market revenue.
North America led the market in 2025 with an estimated 45% share.
Growth is driven by rising adoption of gene and cell therapies, expanding CDMO manufacturing capacity, and growing demand for plasmid DNA in mRNA vaccine production.